<DOC>
	<DOCNO>NCT01861223</DOCNO>
	<brief_summary>To find optimal dose afatinib nimotuzumab patient acquire resistance gefitinib erlotinib .</brief_summary>
	<brief_title>Afatinib Plus Nimotuzumb NSCLC</brief_title>
	<detailed_description />
	<criteria>Histologically confirm diagnosis stage IIIB IV NSCLC Presence EGFR sensitize mutation ( L858R mutation exon 21 exon 19 deletion ) response RECIST prior gefitinib erlotinib stable disease prior gefitinib erlotinib least 6 month Disease progression treatemtn gefitinib erlotinib within 30 day Biopsy disease progression Age ≥20 year ECOG performance status 0 , 1 , 2 Measurable disease criterion RECIST 1.1 Adequate organ function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; total bilirubin ≤1.5 UNL ; AST and/or ALT &lt; 5 UNL ; creatinine clearance ≥ 45 mL/min Known interstitial lung disease Prior treatment EGFR target antibody BIBW 2992 Prior three line chemotherapy advance NSCLC Significant bowel disease impair drug absorption Uncontrolled systemic illness DM , CHF , unstable angina , hypertension arrhythmia Have symptomatic , untreated , uncontrolled central nervous system ( CNS ) metastasis . Patients treat CNS metastasis eligible provided disease radiographically stable , asymptomatic , corticosteroid use discontinue least 2 week prior first dose study drug . Screening asymptomatic patient without history CNS metastases require .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>acquire resistance</keyword>
	<keyword>gefitinib</keyword>
	<keyword>erlotinib</keyword>
</DOC>